Welcome to our dedicated page for Butterfly Network news (Ticker: BFLY), a resource for investors and traders seeking the latest updates and insights on Butterfly Network stock.
Butterfly Network, Inc. develops semiconductor-based ultrasound devices, programmable cloud software and AI for medical imaging and sensing. Its Ultrasound-on-Chip technology underpins handheld whole-body ultrasound systems such as Butterfly iQ, iQ+ and iQ3, along with enterprise workflow software including Compass AI and developer tools such as Butterfly Garden.
Company news commonly covers financial results, point-of-care ultrasound adoption, FDA-cleared AI tools such as its Gestational Age Tool, U.S. and international sales channels, and platform initiatives. Updates also address Butterfly Embedded, the company’s licensing and co-development effort for applying its ultrasound chip and software platform in partner-built products, as well as board and leadership changes tied to medtech, clinical strategy and commercialization.
Butterfly Network (NYSE: BFLY) announced the appointment of Caroll H. Neubauer to its Board of Directors, effective May 18, 2026. He will join the Board’s Compensation and Technology Committees.
Mr. Neubauer spent three decades at B. Braun, helping grow annual revenue from about $1 billion to more than $8 billion, and serves as an executive advisor to Water Street Healthcare Partners. He received AdvaMed’s Lifetime Achievement Award in 2024 and holds law degrees from Freiburg and Georgetown.
Butterfly Network (NYSE: BFLY) will present at the Bank of America Securities 2026 Global Healthcare Conference on May 12, 2026 at 4:35 PM PT. Joseph DeVivo, President, CEO & Chairman, and John Doherty, EVP & CFO, will present and hold one-on-one investor meetings.
A webcast will be available in the Events & Presentations section of the Butterfly investor website. Investors should contact their Bank of America representative to schedule one-on-one meetings.
Butterfly Network (NYSE: BFLY) reported Q1 2026 results with $26.5M revenue (25% YoY), 68.9% gross margin, adjusted EBITDA loss of $6.1M (improved vs prior year), net loss of $12.7M, and cash of $138.0M. Company reaffirmed FY26 revenue guidance of $117M–$121M and adjusted EBITDA loss guidance of $21M–$25M. Key operational updates include FDA clearance for a gestational age AI tool, expansion of the Butterfly Garden partner ecosystem to 30 partners, progress on Home & Community Care commercialization, and growth in Butterfly Embedded partnerships.
Butterfly Network (NYSE: BFLY) named Arun Nagdev, MD as Chief Medical Officer – Point-of-Care Ultrasound (POCUS) on April 21, 2026. Dr. Nagdev will lead global medical strategy for POCUS, clinical product validation, customer engagement, and support regulatory and clinical development efforts.
He brings more than 20 years of POCUS experience, academic roles at UCSF, emergency ultrasound leadership, prior VP clinical experience at Exo, and advisory work with Philips and Fujifilm SonoSite.
Butterfly Network (NYSE: BFLY) will report first quarter 2026 financial results on April 30, 2026 at 8:00 am ET. A live conference call and webcast featuring CEO Joseph DeVivo and CFO John Doherty will precede the market open to discuss financial performance and operational progress.
Live listen-only webcast access and global dial-in numbers are provided; a replay will be available through May 7, 2026.
Butterfly Network (NYSE: BFLY) received FDA clearance for a fully automated Gestational Age (GA) Tool integrated into its handheld ultrasound and app. The AI-powered blind-sweep tool estimates gestational age in under two minutes for 16–37 weeks, trained on >21 million images and deployed in Malawi and Uganda.
The clearance positions Butterfly to expand maternal-health access in low-resource settings and rural U.S. communities, supported in part by a Gates Foundation grant.
Butterfly Network (NYSE: BFLY) appointed David Horsley, Ph.D., as Senior Vice President, Innovation — Butterfly Embedded on March 10, 2026. He will lead strategy, product development, partnerships and commercialization for the Ultrasound-on-Chip™ co-development and licensing initiative. The program aims to embed Butterfly’s semiconductor ultrasound into new products; the company reports a growing pipeline and early collaborations that are contributing revenue.
Dr. Horsley brings MEMS and ultrasonic sensor commercialization experience, including co-founding Chirp Microsystems and prior roles at TDK, Hewlett Packard Laboratories, Northeastern University, and UC Berkeley.
Butterfly Network (NYSE: BFLY) reported record Q4 2025 revenue of $31.5M (41% YoY) and positive operating cash flow in Q4, driving the lowest annual cash usage in company history. The Midjourney partnership contributed $6.8M of Q4 revenue and up to $74M over five years.
GAAP gross margin rose to 67.3%, net loss narrowed to $15.3M, cash and equivalents were $150.5M, and 2026 guidance targets revenue of $117M–$121M with adjusted EBITDA loss of $21M–$25M.
Butterfly Network (NYSE: BFLY) will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026. The company presentation is scheduled for 11:50 AM ET, with senior management hosting one-on-one investor meetings.
Presenters include Joseph DeVivo (President, CEO & Chairman), John Doherty (EVP, CFO) and Megan Carlson (SVP, Accounting & Finance). A webcast will be available in the Events & Presentations section of Butterfly’s investor website.
Butterfly Network (NYSE: BFLY) announced GovRAMP and TX-RAMP authorizations for its Butterfly iQ+/iQ3 probes and Compass AI™ cloud workflow, enabling sales to all state and local government agencies including Texas.
The solution completed a third-party assessment by A-LIGN and a GovRAMP PMO quality review; Butterfly is pursuing FedRAMP in 2026 and additional certifications.